Oppenheimer Starts Celgene (CELG) at Outperform
Get Alerts CELG Hot Sheet
Rating Summary:
7 Buy, 27 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 11 | New: 6
Join SI Premium – FREE
Oppenheimer initiates coverage on Celgene (NASDAQ: CELG) with a Outperform rating and a price target of $141.00.
Analyst Leah Rush Cann commented, "We are initiating coverage of Celgene Corporation, a high-quality biotechnology company with exciting potential new products, with an Outperform rating. We estimate Celgene’s revenue will grow at a compound annual growth rate of 19% per year for the next five years, with product growth of 19.2% per year. Diluted GAAP earnings per share are estimated to grow at a CAGR of 31% over the next five years."
For an analyst ratings summary and ratings history on Celgene click here. For more ratings news on Celgene click here.
Shares of Celgene closed at $121.06 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Intermediate Capital Group (ICP:LN) (ICGUF) PT Raised to GBP22.50 at Citi
- Community Health (CYH) PT Lowered to $4.50 at Oppenheimer
- Jet2 plc (JET2:LN) (DRTGF) PT Raised to GBP20 at RBC Capital
Create E-mail Alert Related Categories
Analyst Comments, Hot New Coverage, New CoverageRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!